Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 10/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874684 | 0.91 | P2RY1 (0.67) | P2RY1EPHX2IGF1RSTING1 | |
| SCHEMBL2877421 | 0.90 | NPC1 (0.60) | P2RY1EPHX2IGF1RNPC1RAB9A | |
| SCHEMBL2877898 | 0.86 | EPHX2 (0.68) | P2RY1EPHX2IGF1RNPC1RAB9A | |
| SCHEMBL2869182 | 0.84 | P2RY1 (0.56) | P2RY1EPHX2IGF1RSTING1 | |
| SCHEMBL2878559 | 0.84 | MAPT (0.59) | P2RY1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14640383 | 0.83 | EPHX2 (0.59) | P2RY1EPHX2IGF1RSTING1 | |
| SCHEMBL2872551 | 0.83 | EPHX2 (0.62) | P2RY1EPHX2IGF1RNPC1RAB9A | |
| SCHEMBL2878243 | 0.83 | P2RY1 (0.56) | P2RY1EPHX2STING1 | |
| SCHEMBL2873322 | 0.82 | EGFR (0.58) | P2RY1EPHX2NPC1RAB9A | |
| SCHEMBL2875822 | 0.81 | P2RY1 (0.60) | P2RY1EPHX2STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | claimed |
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY11, P2RY1, P2RY13 | P2RY1 2/4885EPHX2 1294/4885IGF1R 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.